anurajms/meta_analysis huggingface dataset:
MESH terms:
Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension
1. Adrenergic beta‐Antagonists [*pharmacology]; 2. Antihypertensive Agents [pharmacology]; 3. Blood Pressure [*drug effects]; 4. Dose‐Response Relationship, Drug; 5. Heart Rate [drug effects]; 6. Hypertension [*drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
First‐line beta‐blockers versus other antihypertensive medications for chronic type B aortic dissection
1. Adrenergic beta‐Antagonists [*therapeutic use]; 2. Antihypertensive Agents [*therapeutic use]; 3. Aortic Aneurysm, Thoracic [*drug therapy, etiology]; 4. Aortic Dissection [*drug therapy, etiology]; 5. Hypertension [complications, drug therapy];
MESH terms:
Insulin for glycaemic control in acute ischaemic stroke
1. Blood Glucose [*metabolism]; 2. Diabetes Mellitus [mortality]; 3. Hyperglycemia [blood, complications, *drug therapy, mortality]; 4. Hypoglycemia [blood, complications, mortality]; 5. Hypoglycemic Agents [*administration & dosage]; 6. Insulin [*administration & dosage]; 7. Prognosis; 8. Randomized Controlled Trials as Topic; 9. Reference Values; 10. Stroke [*blood, complications];
MESH terms:
Endovascular repair of abdominal aortic aneurysm
1. Aortic Aneurysm, Abdominal [*surgery]; 2. Aortic Rupture [prevention & control]; 3. Cause of Death; 4. Endovascular Procedures [adverse effects, *methods, mortality]; 5. Randomized Controlled Trials as Topic; 6. Reoperation [statistics & numerical data]; 7. Watchful Waiting;
MESH terms:
Antibiotics and antiseptics for venous leg ulcers
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Anti‐Infective Agents, Local [*therapeutic use]; 3. Occlusive Dressings; 4. Randomized Controlled Trials as Topic; 5. Varicose Ulcer [*drug therapy, microbiology]; 6. Wound Healing;
MESH terms:
Intravascular brachytherapy for peripheral vascular disease
1. Angioplasty; 2. Brachytherapy [*methods]; 3. Endovascular Procedures [*methods]; 4. Femoral Artery; 5. Peripheral Vascular Diseases [*radiotherapy, therapy]; 6. Popliteal Artery; 7. Quality of Life; 8. Radiotherapy, Adjuvant; 9. Randomized Controlled Trials as Topic; 10. Stents; 11. Vascular Patency;
MESH terms:
Treatment of hypertension in peripheral arterial disease
1. Antihypertensive Agents [*therapeutic use]; 2. Hypertension [complications, *drug therapy]; 3. Intermittent Claudication [complications, drug therapy]; 4. Peripheral Vascular Diseases [complications, *drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Immunosuppressive T‐cell antibody induction for heart transplant recipients
1. *Heart Transplantation; 2. Antibodies, Monoclonal [immunology, *therapeutic use]; 3. Antibodies, Monoclonal, Humanized [therapeutic use]; 4. Antilymphocyte Serum [immunology]; 5. Basiliximab; 6. Daclizumab; 7. Graft Rejection [immunology, *prevention & control]; 8. Immunoglobulin G [therapeutic use]; 9. Immunosuppression Therapy [*methods]; 10. Muromonab‐CD3 [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Receptors, Interleukin‐2 [*antagonists & inhibitors, immunology]; 13. Recombinant Fusion Proteins [therapeutic use]; 14. T‐Lymphocytes [*immunology];
MESH terms:
Blood pressure targets for hypertension in people with diabetes mellitus
1. *Blood Pressure; 2. Diabetic Angiopathies [*drug therapy, mortality]; 3. Diastole; 4. Hypertension [*drug therapy, mortality]; 5. Randomized Controlled Trials as Topic; 6. Reference Values; 7. Stroke [prevention & control]; 8. Systole;
MESH terms:
Corticosteroids for viral myocarditis
1. Acute Disease; 2. Adrenal Cortex Hormones [therapeutic use]; 3. Azathioprine [therapeutic use]; 4. Chronic Disease; 5. Cyclosporine [therapeutic use]; 6. Myocarditis [*drug therapy, enzymology, *virology]; 7. Prednisone [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Virus Diseases [*drug therapy];
MESH terms:
Beta blockers for peripheral arterial disease
1. Adrenergic beta‐Antagonists [*adverse effects]; 2. Atenolol [adverse effects]; 3. Intermittent Claudication [*drug therapy]; 4. Metoprolol [adverse effects]; 5. Peripheral Vascular Diseases [*drug therapy]; 6. Pindolol [adverse effects]; 7. Propranolol [adverse effects]; 8. Randomized Controlled Trials as Topic; 9. Regional Blood Flow [drug effects]; 10. Walking;
MESH terms:
Nitrates for acute heart failure syndromes
1. Acute Disease; 2. Heart Failure [*drug therapy]; 3. Isosorbide Dinitrate [therapeutic use]; 4. Nitrates [*therapeutic use]; 5. Nitroglycerin [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Syndrome; 8. Vasodilator Agents [*therapeutic use];
MESH terms:
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
1. Anticoagulants [*administration & dosage, adverse effects]; 2. Drug Administration Schedule; 3. Hemorrhage [chemically induced]; 4. Heparin, Low‐Molecular‐Weight [*administration & dosage, adverse effects]; 5. Pulmonary Embolism [drug therapy]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Thromboembolism [*drug therapy]; 9. Venous Thrombosis [*drug therapy];
MESH terms:
Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post‐stroke spasticity
1. *Patient Care Team; 2. Botulinum Toxins [*therapeutic use]; 3. Muscle Spasticity [drug therapy, etiology, *rehabilitation]; 4. Neuromuscular Agents [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Stroke [*complications, drug therapy];
MESH terms:
Occupational therapy for care home residents with stroke
1. *Nursing Homes; 2. *Stroke Rehabilitation; 3. Activities of Daily Living; 4. Disabled Persons [*rehabilitation]; 5. Occupational Therapy [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Early versus delayed mobilisation for aneurysmal subarachnoid haemorrhage
1. *Bed Rest [mortality]; 2. *Early Ambulation [mortality]; 3. Secondary Prevention; 4. Subarachnoid Hemorrhage [mortality, *prevention & control]; 5. Time Factors; 6. Treatment Outcome;
MESH terms:
Continuous versus intermittent physiological monitoring for acute stroke
1. Blood Pressure [physiology]; 2. Body Temperature [physiology]; 3. Heart Rate [physiology]; 4. Hospital Units [standards]; 5. Institutionalization; 6. Length of Stay; 7. Monitoring, Physiologic [methods]; 8. Oxygen [metabolism]; 9. Pulse; 10. Quality of Health Care; 11. Randomized Controlled Trials as Topic; 12. Stroke [complications, mortality, *physiopathology]; 13. Time Factors;
MESH terms:
Flavonoids for treating venous leg ulcers
1. Flavonoids [*therapeutic use]; 2. Hydroxyethylrutoside [therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Varicose Ulcer [*drug therapy];
MESH terms:
Cholesterol‐reducing agents for aneurysmal subarachnoid haemorrhage
1. Anticholesteremic Agents [*therapeutic use]; 2. Brain Ischemia [epidemiology, *prevention & control]; 3. Incidence; 4. Randomized Controlled Trials as Topic; 5. Simvastatin [*therapeutic use]; 6. Subarachnoid Hemorrhage [complications, *drug therapy]; 7. Treatment Outcome;
MESH terms:
Non‐pharmacological interventions for preventing secondary vascular events after stroke or transient ischemic attack
1. Hypertension [prevention & control]; 2. Ischemic Attack, Transient [*prevention & control]; 3. Myocardial Infarction [*prevention & control]; 4. Randomized Controlled Trials as Topic; 5. Risk Factors; 6. Secondary Prevention [*methods]; 7. Stroke [*prevention & control];
MESH terms:
Physical rehabilitation for older people in long‐term care
1. *Long‐Term Care; 2. *Rehabilitation; 3. Activities of Daily Living; 4. Cognition Disorders [rehabilitation]; 5. Exercise Therapy; 6. Homes for the Aged; 7. Nursing Homes; 8. Randomized Controlled Trials as Topic;
MESH terms:
Hypothermia for neuroprotection in children after cardiopulmonary arrest
1. Brain Injuries [*prevention & control]; 2. Heart Arrest [*complications]; 3. Hypothermia, Induced [*methods];
MESH terms:
Wolbachia‐carrying Aedes mosquitoes for preventing dengue infection
1. *Aedes [microbiology]; 2. *Dengue [prevention & control]; 3. *Dengue Virus; 4. Mosquito Vectors [microbiology]; 5. *Wolbachia;
MESH terms:
Vaccines for preventing herpes zoster in older adults
1. *Chickenpox [chemically induced, drug therapy]; 2. *Herpes Zoster [chemically induced, drug therapy, prevention & control]; 3. *Herpes Zoster Vaccine [adverse effects]; 4. Herpesvirus 3, Human; 5. Vaccines, Attenuated [adverse effects];
MESH terms:
Antiplatelet agents for the treatment of adults with COVID‐19
1. Aspirin; 2. Asymptomatic Infections; 3. *COVID-19; 4. *Platelet Aggregation Inhibitors; 5. SARS-CoV-2;
MESH terms:
Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children
1. Bicarbonates [therapeutic use]; 2. Creatinine; 3. *Dehydration [etiology, therapy]; 4. Diarrhea [therapy]; 5. *Hypokalemia; 6. Potassium; 7. Potassium Chloride [therapeutic use]; 8. Ringer's Lactate; 9. Saline Solution; 10. Sodium;
MESH terms:
Therapeutics for treating mpox in humans
1. Immunoglobulins; 2. *Mpox (monkeypox); 3. *Organophosphonates;
MESH terms:
Hyperimmune immunoglobulin for people with COVID‐19
1. *COVID-19 [therapy, virology]; 2. *COVID-19 Serotherapy; 3. *Immunoglobulins [therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. SARS-CoV-2 [genetics];
MESH terms:
Remdesivir for the treatment of COVID‐19
1. *COVID-19; 2. COVID-19 Drug Treatment; 3. Disease Progression; 4. Randomized Controlled Trials as Topic; 5. SARS-CoV-2;
MESH terms:
Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence
1. Adrenal Cortex Hormones [adverse effects]; 2. *COVID-19 Drug Treatment; 3. Dexamethasone [adverse effects]; 4. *Invasive Fungal Infections; 5. Methylprednisolone; 6. Post-Acute COVID-19 Syndrome; 7. Randomized Controlled Trials as Topic;
MESH terms:
Ivermectin for preventing and treating COVID‐19
1. *COVID-19; 2. Ivermectin [adverse effects]; 3. Randomized Controlled Trials as Topic; 4. Respiration, Artificial; 5. SARS-CoV-2; 6. Severity of Illness Index;
MESH terms:
SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19
1. Antibodies, Monoclonal [adverse effects]; 2. Antibodies, Monoclonal, Humanized; 3. Antibodies, Neutralizing; 4. *Antineoplastic Agents, Immunological; 5. *COVID-19 [prevention & control]; 6. SARS-CoV-2;
MESH terms:
Janus kinase inhibitors for the treatment of COVID‐19
1. Antiviral Agents [therapeutic use]; 2. *Coinfection; 3. *COVID-19 Drug Treatment; 4. *Janus Kinase Inhibitors [therapeutic use]; 5. Oxygen; 6. Randomized Controlled Trials as Topic; 7. SARS-CoV-2; 8. United States;
MESH terms:
Inhaled corticosteroids for the treatment of COVID‐19
1. Adrenal Cortex Hormones; 2. Cause of Death; 3. *COVID-19 Drug Treatment; 4. Respiration, Artificial; 5. SARS-CoV-2;
MESH terms:
Antibiotics for the treatment of COVID‐19
1. Anti-Bacterial Agents [adverse effects]; 2. Cause of Death; 3. *COVID-19; 4. Respiration, Artificial; 5. SARS-CoV-2;
MESH terms:
Colchicine for the treatment of COVID‐19
1. Cause of Death; 2. *Colchicine [adverse effects]; 3. *COVID-19; 4. Quality of Life; 5. SARS-CoV-2;
MESH terms:
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
1. Antibodies, Monoclonal [therapeutic use]; 2. Cause of Death; 3. *COVID-19; 4. Randomized Controlled Trials as Topic; 5. *SARS-CoV-2;
MESH terms:
Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV
1. *Antibiotics, Antitubercular [therapeutic use]; 2. *HIV Infections [complications, drug therapy]; 3. Lipopolysaccharides; 4. *Mycobacterium tuberculosis; 5. Rifampin; 6. Sensitivity and Specificity; 7. *Tuberculosis [diagnosis, drug therapy]; 8. *Tuberculosis, Pulmonary [drug therapy];
MESH terms:
Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta‐analysis
1. *Lower Urinary Tract Symptoms [surgery, therapy]; 2. Network Meta-Analysis; 3. *Prostatic Hyperplasia [complications, surgery]; 4. Quality of Life; 5. *Transurethral Resection of Prostate [adverse effects];
MESH terms:
Effect of mass deworming with antihelminthics for soil‐transmitted helminths during pregnancy
1. Albendazole [administration & dosage]; 2. *Anemia, Iron-Deficiency [parasitology, prevention & control]; 3. *Anthelmintics [administration & dosage]; 4. Bias; 5. Helminthiasis [drug therapy, transmission]; 6. *Intestinal Diseases, Parasitic [drug therapy]; 7. Iron Compounds [administration & dosage]; 8. Perinatal Mortality; 9. *Pregnancy Complications, Hematologic [parasitology, prevention & control]; 10. *Pregnancy Complications, Parasitic [drug therapy, etiology]; 11. Pregnancy Outcome; 12. Pregnancy Trimester, Second; 13. Pregnancy Trimester, Third; 14. Randomized Controlled Trials as Topic; 15. *Soil [parasitology];
MESH terms:
Topical microbicides for preventing sexually transmitted infections
1. Acrylic Resins [administration & dosage]; 2. Adenine [administration & dosage, analogs & derivatives]; 3. Administration, Intravaginal; 4. Agaricales [chemistry]; 5. Anti-HIV Agents [administration & dosage, adverse effects]; 6. Anti-Infective Agents, Local [*administration & dosage]; 7. Bias; 8. Cellulose [administration & dosage, adverse effects, analogs & derivatives]; 9. HIV Infections [prevention & control]; 10. Naphthalenesulfonates [administration & dosage]; 11. Placebos [administration & dosage]; 12. Polymers [administration & dosage]; 13. Pyrimidines [administration & dosage, adverse effects]; 14. Seaweed [chemistry]; 15. Sexually Transmitted Diseases [*prevention & control]; 16. Tenofovir [administration & dosage, adverse effects];
MESH terms:
Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical ventilation
1. Administration, Topical; 2. Anti-Bacterial Agents [*administration & dosage, adverse effects]; 3. Antibiotic Prophylaxis [adverse effects, *methods]; 4. Bias; 5. Critical Care; 6. Cross Infection [mortality, prevention & control]; 7. Hospital Mortality; 8. Pneumonia, Ventilator-Associated [mortality, *prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Respiration, Artificial [*adverse effects]; 11. Respiratory Tract Infections [mortality, *prevention & control];
MESH terms:
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID‐19 infection
1. Anti-Infective Agents [*administration & dosage, adverse effects]; 2. *Betacoronavirus; 3. Coronavirus Infections [prevention & control, *transmission]; 4. COVID-19; 5. *Health Personnel; 6. Infectious Disease Transmission, Patient-to-Professional [*prevention & control]; 7. Mouth [virology]; 8. Mouthwashes [*administration & dosage, adverse effects]; 9. *Nasal Sprays; 10. Nose [virology]; 11. Occupational Diseases [etiology, prevention & control]; 12. Pandemics [prevention & control]; 13. Pneumonia, Viral [prevention & control, *transmission]; 14. SARS-CoV-2; 15. Therapeutic Irrigation;
MESH terms:
Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID‐19 infection to improve patient outcomes and to protect healthcare workers treating them
1. Anti-Infective Agents [*administration & dosage, adverse effects]; 2. *Betacoronavirus; 3. Coronavirus Infections [prevention & control, *therapy, transmission]; 4. COVID-19; 5. *Health Personnel; 6. Infectious Disease Transmission, Patient-to-Professional [*prevention & control]; 7. Mouth [virology]; 8. Mouthwashes [*administration & dosage, adverse effects]; 9. *Nasal Sprays; 10. Nose [virology]; 11. Occupational Diseases [etiology, prevention & control]; 12. Pandemics [prevention & control]; 13. Pneumonia, Viral [prevention & control, *therapy, transmission]; 14. SARS-CoV-2; 15. Therapeutic Irrigation;
MESH terms:
Video calls for reducing social isolation and loneliness in older people: a rapid review
1. *Betacoronavirus; 2. *Coronavirus Infections [epidemiology]; 3. COVID-19; 4. Depression [diagnosis]; 5. Homes for the Aged; 6. Loneliness [*psychology]; 7. Nursing Homes; 8. *Online Social Networking; 9. *Pandemics; 10. *Pneumonia, Viral [epidemiology]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. SARS-CoV-2; 14. Social Control, Informal [methods]; 15. Social Isolation [*psychology];
MESH terms:
Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
1. Antitubercular Agents [*therapeutic use]; 2. Clinical Protocols; 3. Drug Administration Schedule; 4. Drug Combinations; 5. Drug Therapy, Combination [methods]; 6. Randomized Controlled Trials as Topic; 7. Tuberculosis, Pulmonary [*drug therapy];
MESH terms:
Antibiotics for asymptomatic bacteriuria in pregnancy
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Asymptomatic Infections; 3. Bacteriuria [complications, *drug therapy]; 4. Infant, Low Birth Weight; 5. Pregnancy Complications, Infectious [*drug therapy]; 6. Pregnancy Outcome; 7. Premature Birth [prevention & control]; 8. Pyelonephritis [prevention & control]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema
1. Anti‐Bacterial Agents [therapeutic use]; 2. Drainage; 3. Empyema, Pleural [*therapy]; 4. Fibrinolytic Agents [*therapeutic use]; 5. Pleural Effusion [*therapy]; 6. Randomized Controlled Trials as Topic; 7. Streptokinase [therapeutic use]; 8. Thrombolytic Therapy [*methods]; 9. Tissue Plasminogen Activator [therapeutic use]; 10. Urokinase‐Type Plasminogen Activator [therapeutic use];
MESH terms:
Rapid initiation of antiretroviral therapy for people living with HIV
1. Anti-Retroviral Agents [adverse effects, *therapeutic use]; 2. Developing Countries; 3. HIV Infections [*drug therapy, mortality]; 4. Medication Adherence [statistics & numerical data]; 5. Pregnancy Complications, Infectious [drug therapy]; 6. Randomized Controlled Trials as Topic [statistics & numerical data]; 7. Time Factors; 8. *Time-to-Treatment;
MESH terms:
Community‐based antibiotic delivery for possible serious bacterial infections in neonates in low‐ and middle‐income countries
1. *Community Health Services; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Bacterial Infections [*drug therapy]; 4. Developing Countries; 5. Infant Mortality; 6. Randomized Controlled Trials as Topic;
MESH terms:
Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people
1. AIDS-Related Opportunistic Infections [prevention & control]; 2. Antifungal Agents [adverse effects, *therapeutic use]; 3. Candida [drug effects]; 4. Cause of Death; 5. CD4 Lymphocyte Count; 6. Cryptococcosis [mortality, *prevention & control]; 7. Drug Resistance, Fungal; 8. Fluconazole [adverse effects, *therapeutic use]; 9. HIV Seropositivity [*complications, immunology]; 10. Itraconazole [adverse effects, *therapeutic use]; 11. *Primary Prevention; 12. Randomized Controlled Trials as Topic;
MESH terms:
Early versus delayed antiretroviral treatment in HIV‐positive people with cryptococcal meningitis
1. AIDS-Related Opportunistic Infections [drug therapy]; 2. Amphotericin B [administration & dosage, adverse effects]; 3. Anti-HIV Agents [*administration & dosage]; 4. Antifungal Agents [*administration & dosage, adverse effects]; 5. Cause of Death; 6. Drug Administration Schedule; 7. Fluconazole [administration & dosage, adverse effects]; 8. HIV Infections [complications, *drug therapy, mortality]; 9. Meningitis, Cryptococcal [complications, *drug therapy]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Influenza vaccine for chronic obstructive pulmonary disease (COPD)
1. Disease Progression; 2. Influenza Vaccines [adverse effects, *therapeutic use]; 3. Influenza, Human [*prevention & control]; 4. Lung Diseases, Obstructive [*complications]; 5. Randomized Controlled Trials as Topic; 6. Vaccines, Attenuated [adverse effects, therapeutic use]; 7. Vaccines, Inactivated [adverse effects, therapeutic use];
MESH terms:
Interventions for necrotizing soft tissue infections in adults
1. Amoxicillin‐Potassium Clavulanate Combination; 2. Anti‐Bacterial Agents [therapeutic use]; 3. CD28 Antigens [therapeutic use]; 4. Critical Care; 5. Debridement; 6. Fluoroquinolones [therapeutic use]; 7. Immunoglobulins, Intravenous [therapeutic use]; 8. Moxifloxacin; 9. Randomized Controlled Trials as Topic; 10. Soft Tissue Infections [complications, *therapy];
MESH terms:
Interventions to increase influenza vaccination rates of those 60 years and older in the community
1. *Reminder Systems; 2. Attitude of Health Personnel; 3. Community Participation; 4. Health Services Needs and Demand; 5. Immunization Programs [*methods]; 6. Influenza Vaccines [*administration & dosage]; 7. Influenza, Human [*prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Vaccination [*statistics & numerical data];
MESH terms:
Osmotic therapies added to antibiotics for acute bacterial meningitis
1. Adrenal Cortex Hormones [therapeutic use]; 2. Anti‐Bacterial Agents [therapeutic use]; 3. Combined Modality Therapy [methods]; 4. Community‐Acquired Infections [complications, metabolism, mortality, therapy]; 5. Deafness [epidemiology, prevention & control]; 6. Dexamethasone [therapeutic use]; 7. Diuretics, Osmotic [adverse effects, *therapeutic use]; 8. Epilepsy [prevention & control]; 9. Gastrointestinal Hemorrhage [prevention & control]; 10. Glucose [therapeutic use]; 11. Glycerol [adverse effects, *therapeutic use]; 12. Intracranial Pressure [physiology]; 13. Meningitis, Bacterial [complications, metabolism, mortality, *therapy]; 14. Nervous System Diseases [epidemiology, prevention & control]; 15. Osmosis [physiology]; 16. Osmotic Pressure [physiology]; 17. Randomized Controlled Trials as Topic;
MESH terms:
Antidepressants for depression in adults with HIV infection
1. Antidepressive Agents [adverse effects, *therapeutic use]; 2. Confidence Intervals; 3. Depression [drug therapy]; 4. HIV Infections [*psychology]; 5. Patient Dropouts [statistics & numerical data]; 6. Placebos [therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Risk; 10. Selective Serotonin Reuptake Inhibitors [adverse effects, therapeutic use];
MESH terms:
Corticosteroids for pneumonia
1. Adrenal Cortex Hormones [adverse effects, *therapeutic use]; 2. Ampicillin [adverse effects, therapeutic use]; 3. Anti‐Bacterial Agents [therapeutic use]; 4. Budesonide [adverse effects, therapeutic use]; 5. Dexamethasone [adverse effects, therapeutic use]; 6. Hydrocortisone [adverse effects, therapeutic use]; 7. Pneumonia [*drug therapy, mortality]; 8. Prednisolone [adverse effects, therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults
1. *Haemophilus ducreyi; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Azithromycin [therapeutic use]; 4. Chancroid [*drug therapy]; 5. Erythromycin [adverse effects, therapeutic use]; 6. Leucomycins [therapeutic use]; 7. Macrolides [adverse effects, *therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Treatment Outcome;
MESH terms:
Interventions to increase tuberculosis case detection at primary healthcare or community‐level services
1. *Community Health Services; 2. *Patient Acceptance of Health Care; 3. *Primary Health Care; 4. Early Diagnosis; 5. Non‐Randomized Controlled Trials as Topic; 6. Prevalence; 7. Program Evaluation; 8. Randomized Controlled Trials as Topic; 9. Tuberculosis, Pulmonary [*diagnosis, drug therapy, mortality];
MESH terms:
Routine antibiotic prophylaxis after normal vaginal birth for reducing maternal infectious morbidity
1. Amoxicillin [administration & dosage]; 2. Anti-Bacterial Agents [administration & dosage]; 3. *Antibiotic Prophylaxis; 4. Chloramphenicol [administration & dosage]; 5. Clavulanic Acid [administration & dosage]; 6. *Delivery, Obstetric; 7. Endometritis [epidemiology, *prevention & control]; 8. Episiotomy [adverse effects]; 9. Non-Randomized Controlled Trials as Topic; 10. Puerperal Infection [epidemiology, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Sulfamethoxypyridazine [administration & dosage]; 13. Surgical Wound Infection [epidemiology, prevention & control]; 14. Urinary Tract Infections [epidemiology, prevention & control];
MESH terms:
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
1. Acute Disease; 2. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 3. Bacterial Infections [blood, *drug therapy, mortality]; 4. Biomarkers [blood]; 5. Calcitonin [*blood]; 6. Calcitonin Gene‐Related Peptide; 7. Cause of Death; 8. Protein Precursors [*blood]; 9. Randomized Controlled Trials as Topic; 10. Respiratory Tract Infections [blood, *drug therapy, mortality]; 11. Treatment Failure;
MESH terms:
Short‐course versus long‐course intravenous therapy with the same antibiotic for severe community‐acquired pneumonia in children aged two months to 59 months
1. Anti‐Bacterial Agents [*administration & dosage]; 2. Community‐Acquired Infections [drug therapy]; 3. Drug Administration Schedule; 4. Injections, Intravenous; 5. Pneumonia [*drug therapy]; 6. Time Factors;
MESH terms:
Intravenous immunoglobulin for the treatment of childhood encephalitis
1. Bias; 2. Disability Evaluation; 3. Encephalitis, Japanese [therapy]; 4. Encephalitis, Viral [*therapy]; 5. Glasgow Coma Scale; 6. Immunoglobulins, Intravenous [adverse effects, *therapeutic use]; 7. Length of Stay; 8. Placebos [therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Probiotics for preventing urinary tract infection in people with neuropathic bladder
1. *Escherichia coli; 2. Probiotics [adverse effects, *therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Urinary Bladder, Neurogenic [*complications]; 5. Urinary Tract Infections [*prevention & control];
MESH terms:
Isoniazid for preventing tuberculosis in HIV‐infected children
1. AIDS-Related Opportunistic Infections [mortality, *prevention & control]; 2. Anti-HIV Agents [therapeutic use]; 3. Antitubercular Agents [adverse effects, *therapeutic use]; 4. HIV Infections [drug therapy, *mortality]; 5. Incidence; 6. Isoniazid [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects, therapeutic use]; 9. Tuberculosis, Multidrug-Resistant [epidemiology]; 10. Tuberculosis, Pulmonary [drug therapy, *mortality, *prevention & control];
MESH terms:
Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
1. Acute Disease; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Bronchiolitis [*complications, virology]; 4. Clarithromycin [*therapeutic use]; 5. Cough [*drug therapy, etiology]; 6. Randomized Controlled Trials as Topic; 7. Respiratory Sounds [*drug effects, etiology]; 8. Respiratory Syncytial Virus Infections [complications, *drug therapy];
MESH terms:
Zinc supplementation for the treatment of measles in children
1. Fever [therapy]; 2. Measles [complications, mortality, *therapy]; 3. Pneumonia [therapy]; 4. Randomized Controlled Trials as Topic; 5. Zinc [*administration & dosage, deficiency];
MESH terms:
Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
1. Administration, Oral; 2. Anti‐Bacterial Agents [administration & dosage]; 3. Bronchitis, Chronic [mortality, *prevention & control]; 4. Disease Progression; 5. Haemophilus Vaccines [*administration & dosage]; 6. Haemophilus influenzae [*immunology]; 7. Pulmonary Disease, Chronic Obstructive [mortality, *prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Secondary Prevention; 10. Tablets, Enteric‐Coated;
MESH terms:
Antibiotics for acute bronchitis
1. Acute Disease; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Bronchitis [*drug therapy]; 4. Cough [drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Pre‐admission antibiotics for suspected cases of meningococcal disease
1. *Antibiotic Prophylaxis; 2. Anti‐Bacterial Agents [therapeutic use]; 3. Ceftriaxone [therapeutic use]; 4. Chloramphenicol [therapeutic use]; 5. Injections, Intramuscular; 6. Meningitis, Meningococcal [complications, drug therapy, mortality]; 7. Meningococcal Infections [complications, *drug therapy, mortality]; 8. Patient Admission;
MESH terms:
Nasal decontamination for the prevention of surgical site infection in Staphylococcus aureus carriers
1. *Cardiac Surgical Procedures; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Anti‐Infective Agents, Local [*therapeutic use]; 4. Carrier State [*drug therapy]; 5. Chlorhexidine [therapeutic use]; 6. Drug Combinations; 7. Iodine [therapeutic use]; 8. Mupirocin [therapeutic use]; 9. Nose [*microbiology]; 10. Randomized Controlled Trials as Topic; 11. Staphylococcal Infections [*drug therapy, mortality]; 12. Staphylococcus aureus; 13. Surgical Wound Infection [*prevention & control];
MESH terms:
Surgical versus non‐surgical management for pleural empyema
1. *Thoracic Surgery, Video‐Assisted [adverse effects, mortality]; 2. *Thoracostomy [adverse effects, mortality]; 3. Drainage [adverse effects, methods, mortality]; 4. Empyema, Pleural [mortality, surgery, *therapy]; 5. Length of Stay; 6. Randomized Controlled Trials as Topic; 7. Selection Bias; 8. Thrombolytic Therapy;
MESH terms:
Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
1. Anti‐Bacterial Agents [therapeutic use]; 2. Biomarkers [blood]; 3. Calcitonin [*blood]; 4. Intensive Care Units; 5. Patient Discharge; 6. Randomized Controlled Trials as Topic; 7. Sepsis [*blood, drug therapy, *mortality]; 8. Shock, Septic [blood, drug therapy, mortality]; 9. Time Factors;
MESH terms:
Dressings for the prevention of surgical site infection
1. *Bandages; 2. Alginates [administration & dosage]; 3. Bandages, Hydrocolloid; 4. Biguanides; 5. Disinfectants; 6. Randomized Controlled Trials as Topic; 7. Silver [administration & dosage]; 8. Surgical Wound Infection [classification, *prevention & control]; 9. Wound Healing;
MESH terms:
Antiviral agents for infectious mononucleosis (glandular fever)
1. Acute Disease; 2. Acyclovir [adverse effects, *analogs & derivatives, *therapeutic use]; 3. Antiviral Agents [adverse effects, *therapeutic use]; 4. Guanine [adverse effects, *analogs & derivatives, therapeutic use]; 5. Infectious Mononucleosis [*drug therapy]; 6. Randomized Controlled Trials as Topic; 7. Valacyclovir; 8. Valine [adverse effects, *analogs & derivatives, therapeutic use];
MESH terms:
One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates
1. Anti‐Bacterial Agents [*administration & dosage, adverse effects, pharmacokinetics]; 2. Drug Administration Schedule; 3. Gentamicins [*administration & dosage, adverse effects, pharmacokinetics]; 4. Hearing [drug effects]; 5. Kidney [drug effects]; 6. Randomized Controlled Trials as Topic; 7. Sepsis [*drug therapy, metabolism];
MESH terms:
School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents
1. *Contraception; 2. Herpes Genitalis [epidemiology, *prevention & control, transmission]; 3. Herpesvirus 2, Human; 4. HIV Infections [epidemiology, *prevention & control, transmission]; 5. *Pregnancy in Adolescence; 6. Program Evaluation; 7. Randomized Controlled Trials as Topic; 8. Reward; 9. *School Health Services; 10. Sex Education; 11. Sexually Transmitted Diseases [prevention & control]; 12. Syphilis [epidemiology, *prevention & control];
MESH terms:
Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
1. *Wound Healing; 2. Administration, Topical; 3. Anti‐Bacterial Agents; 4. Anti‐Infective Agents, Local [*administration & dosage, adverse effects]; 5. Dermatitis, Allergic Contact [etiology]; 6. Drug Resistance, Bacterial; 7. Randomized Controlled Trials as Topic; 8. Surgical Wound Infection [*prevention & control];
MESH terms:
Fluid therapy for acute bacterial meningitis
1. Acute Disease; 2. Developing Countries; 3. Fluid Therapy [adverse effects, methods, *standards]; 4. Hyponatremia [etiology]; 5. Meningitis, Bacterial [complications, *therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotics for ventilator‐associated pneumonia
1. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 2. Carbapenems [therapeutic use]; 3. Cause of Death; 4. Drug Therapy, Combination [mortality]; 5. Empirical Research; 6. Pneumonia, Ventilator‐Associated [*drug therapy, mortality]; 7. Randomized Controlled Trials as Topic;
MESH terms:
HIV prevention advice for people with serious mental illness
1. *Sexual Behavior; 2. HIV Infections [*prevention & control]; 3. Mental Disorders [*complications];
MESH terms:
Interventions for men and women with their first episode of genital herpes
1. Acyclovir [adverse effects, analogs & derivatives, therapeutic use]; 2. Administration, Oral; 3. Antiviral Agents [adverse effects, therapeutic use]; 4. Herpes Genitalis [*drug therapy]; 5. Injections, Intravenous; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Valacyclovir; 9. Valine [adverse effects, analogs & derivatives, therapeutic use];
MESH terms:
Exercise prior to influenza vaccination for limiting influenza incidence and its related complications in adults
1. *Exercise; 2. *Vaccination; 3. Incidence; 4. Influenza Vaccines [*administration & dosage, adverse effects]; 5. Influenza, Human [complications, epidemiology, *prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Resistance Training [methods]; 8. Time Factors; 9. Walking;
MESH terms:
Behavioral interventions for improving contraceptive use among women living with HIV
1. *Contraception Behavior; 2. *HIV Seronegativity; 3. *HIV Seropositivity; 4. Condoms [statistics & numerical data]; 5. Contraceptive Agents, Female [*administration & dosage]; 6. Family Planning Services; 7. Pregnancy Rate;
MESH terms:
Corticosteroids for treating nerve damage in leprosy
1. Glucocorticoids [administration & dosage, adverse effects, *therapeutic use]; 2. Leprosy [*complications]; 3. Methylprednisolone [therapeutic use]; 4. Peripheral Nervous System Diseases [diagnosis, *drug therapy, etiology]; 5. Prednisolone [administration & dosage, therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Somatosensory Disorders [diagnosis, *drug therapy, etiology];
MESH terms:
Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis
1. *Primary Prevention; 2. *Secondary Prevention; 3. Anticonvulsants [*therapeutic use]; 4. Encephalitis, Viral [*complications]; 5. Seizures [etiology, *prevention & control];
MESH terms:
Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis
1. Antitubercular Agents [*administration & dosage]; 2. Drug Combinations; 3. Drug Therapy, Combination [methods]; 4. Medication Adherence; 5. Randomized Controlled Trials as Topic; 6. Tuberculosis, Pulmonary [*drug therapy];
MESH terms:
Systemic antifungal therapy for tinea capitis in children
1. Antifungal Agents [*therapeutic use]; 2. Fluconazole [therapeutic use]; 3. Griseofulvin [therapeutic use]; 4. Itraconazole [therapeutic use]; 5. Ketoconazole [therapeutic use]; 6. Naphthalenes [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Terbinafine; 9. Tinea Capitis [*drug therapy];
MESH terms:
Corticosteroids for managing tuberculous meningitis
1. Antitubercular Agents [*therapeutic use]; 2. Chemotherapy, Adjuvant; 3. Dexamethasone [therapeutic use]; 4. Glucocorticoids [*therapeutic use]; 5. Hydrocortisone [therapeutic use]; 6. Intention to Treat Analysis; 7. Prednisolone [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Tuberculosis, Meningeal [*drug therapy, mortality];
MESH terms:
Early removal versus expectant management of central venous catheters in neonates with bloodstream infection
1. *Bacteremia; 2. *Watchful Waiting; 3. Catheter‐Related Infections [*blood, prevention & control]; 4. Catheterization, Central Venous [*instrumentation]; 5. Catheters, Indwelling [*adverse effects]; 6. Device Removal [*standards]; 7. Time Factors;
MESH terms:
Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women
1. Antacids [*urine]; 2. Anti‐Infective Agents, Urinary [therapeutic use]; 3. Hydrogen‐Ion Concentration [drug effects]; 4. Urinary Tract Infections [*drug therapy, urine]; 5. Urine [chemistry];
MESH terms:
Antihelminthics in helminth‐endemic areas: effects on HIV disease progression
1. *Endemic Diseases; 2. Anthelmintics [*therapeutic use]; 3. CD4 Lymphocyte Count; 4. Disease Progression; 5. HIV Infections [immunology, *parasitology, virology]; 6. HIV‐1 [*genetics]; 7. Health Resources; 8. Helminthiasis [complications, *drug therapy]; 9. Poverty Areas; 10. RNA, Viral [analysis]; 11. Randomized Controlled Trials as Topic; 12. Viral Load;
MESH terms:
Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates
1. *Infant, Low Birth Weight; 2. *Infant, Premature; 3. Administration, Oral; 4. Enterocolitis, Necrotizing [*prevention & control]; 5. Immunoglobulin A [*administration & dosage]; 6. Immunoglobulin G [*administration & dosage]; 7. Infant, Premature, Diseases [*prevention & control]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotics for preventing suppurative complications from undifferentiated acute respiratory infections in children under five years of age
1. Acute Disease; 2. Amoxicillin‐Potassium Clavulanate Combination [*therapeutic use]; 3. Ampicillin [*therapeutic use]; 4. Anti‐Bacterial Agents [*therapeutic use]; 5. Otitis [*prevention & control]; 6. Pneumonia [*prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Tract Infections [complications, drug therapy]; 9. Suppuration [drug therapy];
MESH terms:
Antithrombin III for critically ill patients
1. Anti‐Inflammatory Agents [adverse effects, *therapeutic use]; 2. Anticoagulants [adverse effects, *therapeutic use]; 3. Antithrombin III [adverse effects, *therapeutic use]; 4. Critical Illness [*mortality]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Frequency of dressing changes for central venous access devices on catheter‐related infections
1. Bandages [*statistics & numerical data]; 2. Catheter‐Related Infections [*epidemiology, mortality]; 3. Cause of Death; 4. Central Venous Catheters [*adverse effects]; 5. Incidence; 6. Pain Measurement; 7. Randomized Controlled Trials as Topic; 8. Skin [injuries]; 9. Surgical Tape [adverse effects]; 10. Time Factors;
MESH terms:
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection
1. *Strongyloides stercoralis; 2. Albendazole [adverse effects, *therapeutic use]; 3. Anthelmintics [adverse effects, *therapeutic use]; 4. Ivermectin [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Strongyloidiasis [*drug therapy]; 7. Thiabendazole [adverse effects, *therapeutic use];
MESH terms:
Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients
1. Amphotericin B [therapeutic use]; 2. Antifungal Agents [*therapeutic use]; 3. Critical Illness [*mortality]; 4. Fluconazole [therapeutic use]; 5. Immunocompromised Host; 6. Mycoses [mortality, *prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Semi‐recumbent position versus supine position for the prevention of ventilator‐associated pneumonia in adults requiring mechanical ventilation
1. *Respiration, Artificial [statistics & numerical data]; 2. Anti‐Bacterial Agents [therapeutic use]; 3. Hospital Mortality; 4. Intensive Care Units [statistics & numerical data]; 5. Length of Stay; 6. Patient Positioning [*methods]; 7. Pneumonia, Ventilator‐Associated [microbiology, mortality, *prevention & control]; 8. Pressure Ulcer [epidemiology]; 9. Randomized Controlled Trials as Topic; 10. Supine Position;
MESH terms:
Linezolid versus vancomycin for skin and soft tissue infections
1. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 2. Drug Eruptions [etiology]; 3. Length of Stay; 4. Linezolid [adverse effects, *therapeutic use]; 5. Pruritus [chemically induced]; 6. Randomized Controlled Trials as Topic; 7. Skin Diseases, Bacterial [*drug therapy]; 8. Soft Tissue Infections [*drug therapy]; 9. Thrombocytopenia [chemically induced]; 10. Vancomycin [adverse effects, *therapeutic use];
MESH terms:
Adjuvant corticosteroids for reducing death in neonatal bacterial meningitis
1. Anti‐Bacterial Agents [therapeutic use]; 2. Cause of Death; 3. Chemotherapy, Adjuvant [methods]; 4. Dexamethasone [*therapeutic use]; 5. Glucocorticoids [*therapeutic use]; 6. Hearing Loss, Sensorineural [etiology]; 7. Meningitis, Bacterial [complications, *drug therapy, mortality]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Duration of treatment for asymptomatic bacteriuria during pregnancy
1. *Asymptomatic Infections; 2. Anti‐Bacterial Agents [*administration & dosage, therapeutic use]; 3. Bacteriuria [*drug therapy]; 4. Drug Administration Schedule; 5. Pregnancy Complications, Infectious [*drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Steroids for symptom control in infectious mononucleosis
1. Adrenal Cortex Hormones [*therapeutic use]; 2. Infectious Mononucleosis [*drug therapy]; 3. Randomized Controlled Trials as Topic;
MESH terms:
Prophylactic oral/topical non‐absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants
1. *Infant, Very Low Birth Weight; 2. Administration, Oral; 3. Administration, Topical; 4. Antifungal Agents [*therapeutic use]; 5. Fluconazole [therapeutic use]; 6. Infant, Premature; 7. Infant, Premature, Diseases [*prevention & control]; 8. Miconazole [therapeutic use]; 9. Mycoses [*prevention & control]; 10. Nystatin [therapeutic use]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants
1. *Infant, Very Low Birth Weight; 2. Antifungal Agents [*therapeutic use]; 3. Developmental Disabilities [etiology, *prevention & control]; 4. Fluconazole [therapeutic use]; 5. Infant, Premature, Diseases [mortality, *prevention & control]; 6. Mycoses [complications, mortality, *prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Prenatal education for congenital toxoplasmosis
1. Hygiene [*education]; 2. Pregnancy Complications, Parasitic [*prevention & control]; 3. Prenatal Care [*methods]; 4. Randomized Controlled Trials as Topic; 5. Rare Diseases [parasitology, *prevention & control]; 6. Toxoplasmosis, Congenital [*prevention & control];
MESH terms:
Antibiotics for preventing lower respiratory tract infections in high‐risk children aged 12 years and under
1. Anemia, Sickle Cell [complications]; 2. Anti-Bacterial Agents [*therapeutic use]; 3. Cystic Fibrosis [complications]; 4. HIV Infections [complications]; 5. Randomized Controlled Trials as Topic; 6. Respiratory Tract Infections [*drug therapy];
MESH terms:
Heliox inhalation therapy for bronchiolitis in infants
1. Acute Disease; 2. Administration, Inhalation; 3. Bronchiolitis, Viral [*drug therapy]; 4. Bronchodilator Agents [*administration & dosage]; 5. Helium [*administration & dosage]; 6. Intensive Care Units, Pediatric [statistics & numerical data]; 7. Intubation, Intratracheal [statistics & numerical data]; 8. Length of Stay; 9. Oxygen [*administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Respiratory Syncytial Virus Infections [*complications];
MESH terms:
Corticosteroids for acute bacterial meningitis
1. Acute Disease; 2. Anti‐Inflammatory Agents [adverse effects, therapeutic use]; 3. Developed Countries; 4. Developing Countries; 5. Dexamethasone [therapeutic use]; 6. Glucocorticoids [adverse effects, *therapeutic use]; 7. Hearing Loss [etiology, prevention & control]; 8. Hydrocortisone [therapeutic use]; 9. Meningitis, Bacterial [complications, *drug therapy, mortality]; 10. Prednisolone [therapeutic use]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Post‐exposure passive immunisation for preventing rubella and congenital rubella syndrome
1. Infusions, Intravenous; 2. Injections, Intramuscular; 3. Post‐Exposure Prophylaxis [*methods]; 4. Prospective Studies; 5. Randomized Controlled Trials as Topic; 6. Rubella [*prevention & control]; 7. Rubella Syndrome, Congenital [*prevention & control]; 8. Sodium Chloride [administration & dosage]; 9. gamma‐Globulins [*administration & dosage];
MESH terms:
Beta2‐agonists for acute cough or a clinical diagnosis of acute bronchitis
1. Acute Disease; 2. Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; 3. Airway Obstruction [drug therapy]; 4. Bronchitis [*drug therapy]; 5. Bronchodilator Agents [therapeutic use]; 6. Cough [*drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Incentives and enablers to improve adherence in tuberculosis
1. *Motivation; 2. *Token Economy; 3. Ill‐Housed Persons; 4. Medication Adherence [psychology, statistics & numerical data]; 5. Patient Compliance [*psychology, statistics & numerical data]; 6. Prisoners; 7. Randomized Controlled Trials as Topic; 8. Substance‐Related Disorders [complications]; 9. Tuberculin Test [psychology]; 10. Tuberculosis, Pulmonary [diagnosis, drug therapy, *psychology];
MESH terms:
Short‐course versus prolonged‐course antibiotic therapy for hospital‐acquired pneumonia in critically ill adults
1. *Critical Illness; 2. Anti‐Bacterial Agents [*administration & dosage]; 3. Cross Infection [*drug therapy]; 4. Drug Administration Schedule; 5. Intensive Care Units; 6. Pneumonia [*drug therapy, microbiology]; 7. Pneumonia, Ventilator‐Associated [drug therapy, microbiology]; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Surfactant therapy for bronchiolitis in critically ill infants
1. Bronchiolitis [*drug therapy]; 2. Critical Illness; 3. Length of Stay; 4. Pulmonary Surfactants [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial [statistics & numerical data]; 7. Time Factors;
MESH terms:
Silver‐coated endotracheal tubes for prevention of ventilator‐associated pneumonia in critically ill patients
1. *Coated Materials, Biocompatible; 2. *Silver; 3. Critical Illness; 4. Intubation, Intratracheal [*instrumentation]; 5. Pneumonia, Ventilator‐Associated [*prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for prevention of herpes simplex labialis (cold sores on the lips)
1. Antiviral Agents [adverse effects, *therapeutic use]; 2. Herpes Labialis [*prevention & control]; 3. Randomized Controlled Trials as Topic; 4. Recurrence; 5. Secondary Prevention [methods];
MESH terms:
Interventions for preventing recurrent urinary tract infection during pregnancy
1. *Secondary Prevention; 2. Anti‐Infective Agents, Urinary [*therapeutic use]; 3. Bacteriuria [prevention & control]; 4. Nitrofurantoin [*therapeutic use]; 5. Pregnancy Complications, Infectious [*prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Urinary Tract Infections [*prevention & control]; 9. Watchful Waiting;
MESH terms:
Vaccines for women for preventing neonatal tetanus
1. Cause of Death; 2. Diphtheria‐Tetanus Vaccine [*therapeutic use]; 3. Influenza Vaccines [administration & dosage]; 4. Randomized Controlled Trials as Topic; 5. Tetanus [mortality, *prevention & control]; 6. Tetanus Toxoid [*therapeutic use];
MESH terms:
Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity
1. *Antibiotic Prophylaxis; 2. Endometritis [*prevention & control]; 3. Fetal Membranes, Premature Rupture [prevention & control]; 4. Fetal Weight [drug effects]; 5. Pregnancy Outcome; 6. Pregnancy Trimester, Second; 7. Pregnancy Trimester, Third; 8. Pregnancy, High‐Risk; 9. Premature Birth [*prevention & control]; 10. Randomized Controlled Trials as Topic; 11. Vaginosis, Bacterial [complications, drug therapy];